Literature DB >> 29708527

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice.

Francesca Ruscitti1, Francesca Ravanetti2, Gaetano Donofrio2, Yanto Ridwan3, Paula van Heijningen3, Jeroen Essers4, Gino Villetti1, Antonio Cacchioli2, Wim Vos5, Franco Fabio Stellari6.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized by the progressive and irreversible destruction of lung architecture, which causes significant deterioration in lung function and subsequent death from respiratory failure. The pathogenesis of IPF in experimental animal models has been induced by bleomycin administration. In this study, we investigate an IPF-like mouse model induced by a double intratracheal bleomycin instillation. Standard histological assessments used for studying lung fibrosis are invasive terminal procedures. The goal of this work is to monitor lung fibrosis through noninvasive imaging techniques such as Fluorescent Molecular Tomography (FMT) and Micro-CT. These two technologies validated with histology findings could represent a revolutionary functional approach for real time non-invasive monitoring of IPF disease severity and progression. The fusion of different approaches represents a step further for understanding the IPF disease, where the molecular events occurring in a pathological condition can be observed with FMT and the subsequent anatomical changes can be monitored by Micro-CT.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29708527      PMCID: PMC5933503          DOI: 10.3791/56443

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  26 in total

1.  Assessment of asthmatic inflammation using hybrid fluorescence molecular tomography-x-ray computed tomography.

Authors:  Xiaopeng Ma; Jaya Prakash; Francesca Ruscitti; Sarah Glasl; Fabio Franco Stellari; Gino Villetti; Vasilis Ntziachristos
Journal:  J Biomed Opt       Date:  2016-01       Impact factor: 3.170

Review 2.  Murine models of pulmonary fibrosis.

Authors:  Bethany B Moore; Cory M Hogaboam
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-11-09       Impact factor: 5.464

Review 3.  Animal models of fibrotic lung disease.

Authors:  Bethany B Moore; William E Lawson; Tim D Oury; Thomas H Sisson; Krishnan Raghavendran; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

4.  Standardized quantification of pulmonary fibrosis in histological samples.

Authors:  Ralf-Harto Hübner; Wolfram Gitter; Nour Eddine El Mokhtari; Micaela Mathiak; Marcus Both; Hendrik Bolte; Sandra Freitag-Wolf; Burkhard Bewig
Journal:  Biotechniques       Date:  2008-04       Impact factor: 1.993

Review 5.  Targeted Delivery of Bleomycin: A Comprehensive Anticancer Review.

Authors:  Zhiqiang Yu; Bo Yan; Liqian Gao; Chenbo Dong; Jian Zhong; Mathew D Ortenzio; Brandon Nguyen; Su Seong Lee; Xianglong Hu; Feng Liang
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

Review 6.  Integrating mechanisms of pulmonary fibrosis.

Authors:  Thomas A Wynn
Journal:  J Exp Med       Date:  2011-07-04       Impact factor: 14.307

7.  Heterologous Matrix Metalloproteinase Gene Promoter Activity Allows In Vivo Real-time Imaging of Bleomycin-Induced Lung Fibrosis in Transiently Transgenized Mice.

Authors:  Fabio Franco Stellari; Francesca Ruscitti; Daniela Pompilio; Francesca Ravanetti; Giulia Tebaldi; Francesca Macchi; Andrea Elizabeth Verna; Gino Villetti; Gaetano Donofrio
Journal:  Front Immunol       Date:  2017-03-01       Impact factor: 7.561

8.  Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography.

Authors:  Ellen De Langhe; Greetje Vande Velde; Jeroen Hostens; Uwe Himmelreich; Benoit Nemery; Frank P Luyten; Jeroen Vanoirbeek; Rik J Lories
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

9.  Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis.

Authors:  Louise Organ; Barbara Bacci; Emmanuel Koumoundouros; Garry Barcham; Marjorie Milne; Wayne Kimpton; Chrishan Samuel; Ken Snibson
Journal:  BMC Pulm Med       Date:  2015-07-31       Impact factor: 3.317

10.  Longitudinal micro-CT provides biomarkers of lung disease that can be used to assess the effect of therapy in preclinical mouse models, and reveal compensatory changes in lung volume.

Authors:  Greetje Vande Velde; Jennifer Poelmans; Ellen De Langhe; Amy Hillen; Jeroen Vanoirbeek; Uwe Himmelreich; Rik J Lories
Journal:  Dis Model Mech       Date:  2015-11-12       Impact factor: 5.758

View more
  5 in total

1.  Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis.

Authors:  Shengren Song; Zhenli Fu; Ruijuan Guan; Jie Zhao; Penghui Yang; Yang Li; Hang Yin; Yunxin Lai; Gencheng Gong; Simin Zhao; Jiangtian Yu; Xiaomin Peng; Ying He; Yumei Luo; Nanshan Zhong; Jin Su
Journal:  Eur Respir J       Date:  2022-05-05       Impact factor: 33.795

2.  The importance of routine quality control for reproducible pulmonary measurements by in vivo micro-CT.

Authors:  Martina Mambrini; Laura Mecozzi; Erica Ferrini; Ludovica Leo; Davide Bernardi; Andrea Grandi; Nicola Sverzellati; Livia Ruffini; Mario Silva; Franco Fabio Stellari
Journal:  Sci Rep       Date:  2022-06-11       Impact factor: 4.996

3.  Macrophage-Targeted Lung Delivery of Dexamethasone Improves Pulmonary Fibrosis Therapy via Regulating the Immune Microenvironment.

Authors:  Xiaoqing Sang; Yuanyuan Wang; Zhifeng Xue; Dawei Qi; Guanwei Fan; Fei Tian; Yan Zhu; Jian Yang
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

4.  In-vivo lung fibrosis staging in a bleomycin-mouse model: a new micro-CT guided densitometric approach.

Authors:  Laura Mecozzi; Martina Mambrini; Francesca Ruscitti; Erica Ferrini; Roberta Ciccimarra; Francesca Ravanetti; Nicola Sverzellati; Mario Silva; Livia Ruffini; Sasha Belenkov; Maurizio Civelli; Gino Villetti; Fabio Franco Stellari
Journal:  Sci Rep       Date:  2020-10-30       Impact factor: 4.379

5.  [18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach.

Authors:  Bertrand Collin; Pierre-Simon Bellaye; Julie Tanguy; Françoise Goirand; Alexanne Bouchard; Jame Frenay; Mathieu Moreau; Céline Mothes; Alexandra Oudot; Alex Helbling; Mélanie Guillemin; Philippe Bonniaud; Alexandre Cochet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-13       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.